Johnson & Johnson Stock
Johnson & Johnson Stock
Johnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
Pros and Cons of Johnson & Johnson in the next few years
Pros
Cons
Performance of Johnson & Johnson vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | 0.410% | -2.611% | -0.135% | 51.543% | 25.580% | 40.208% | 52.879% |
| BioMarin Pharmaceutical Inc. | 1.980% | 1.507% | 4.870% | 2.059% | 3.222% | -33.912% | -18.794% |
| Biogen Inc. | -0.940% | 2.176% | -4.623% | 62.377% | 20.334% | -25.054% | -34.572% |
| Zoetis Inc. A | 0.120% | 0.610% | 4.833% | -49.386% | -38.580% | -61.718% | -61.405% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Johnson & Johnson (JNJ.US) – FY2025 Annual Report
Johnson & Johnson’s financial position appears to have strengthened markedly in fiscal 2025, with revenue reaching nearly $94.2 billion and net income rebounding to approximately $26.8 billion. The year-over-year profit growth of over 90 percent stands out, though this largely reflects a low base in 2024 rather than a purely organic surge. Overall, the company seems to be navigating a dynamic environment with a mix of strong therapeutic performance and meaningful portfolio reshaping through acquisitions.
Revenue growth of about 6 percent was accompanied by a notable divergence in profitability trends. While net margin expanded sharply from around 16 percent to over 28 percent, gross margin edged down from roughly 69 percent to just under 68 percent, continuing a gradual decline from above 71 percent two years earlier. This compression could suggest cost pressures or a shift in product mix, particularly as sales of older immunology therapies like Stelara contracted under biosimilar competition. The dramatic jump in bottom-line profitability appears to have been significantly influenced by a swing in other income and expense items; a substantial net benefit in the current period contrasts with a considerable charge in the prior year, making the earnings improvement less reflective of underlying operating trends alone.
Comments